giant cell arteritis

Updated: Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA

Brief Summary: Primary Objective: To evaluate the efficacy of sarilumab in patients with giant cell arteritis (GCA) as assessed by the proportion of patients with sustained remission for sarilumab compared to placebo, in combination with a corticosteroid (CS) tapering course. Secondary Objective: To demonstrate the efficacy of sarilumab in patients…...

Read more

VF Celebrates Vasculitis Awareness Month 2018

The Vasculitis Foundation, the world’s largest organization dedicated to providing advocacy, education and support for people with vasculitis, announces the launch of Vasculitis Awareness Month (May 2018), an annual effort to create global awareness of the disease that’s so rare that fewer than 200,000 new cases are diagnosed each year.…...

Read more

#GivingTuesday Matching Gift Challenge

#GivingTuesday is a global day of giving fueled by the power of social media and collaboration.  This year your donation can go even further with our generous matching gift challenge! For every dollar donated this year, a special donor will match up to $10,000!  Dollar for dollar! We want to…...

Read more

Introducing our 2017-2018 VCRC-VF Fellow

Kaitlin Quinn, MD, is the recipient of the 2017 VCRC-VF Fellowship.  She received her medical degree from New York Medical College in Valhalla, New York.   She completed her Internal Medicine residency and a two-year Rheumatology fellowship training program at MedStar Georgetown University Hospital in Washington, D.C.  Dr. Quinn is currently…...

Read more

FDA Approves Genentech’s Actemra® for Giant Cell Arteritis

Genentech, a member of the Roche Group, announced today (May 22, 2017) that the U.S. Food and Drug Administration (FDA) has approved Actemra® (tocilizumab) subcutaneous injection for the treatment of GCA, a chronic and severe autoimmune condition. Actemra is the first therapy approved by the FDA for the treatment of…...

Read more